Patient-performed functional tests were found to be reliable, scalable options for assessing muscle function in idiopathic inflammatory myopathies.

Nkarta's NKX019 offers hope for autoimmune treatment. Upcoming trial data and strategic moves could fuel recovery. Read more ...

In immune-mediated inflammatory diseases, the overall risk for serious adverse events is not notably higher with combo ...

FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track – – Enrolling approximately one patient per week across the RESET™ clinical development program since ACR ...

Nkarta is laying off a third of its employees, including half of the biotech’s executive leadership, as the company diverts ...

The FDA bestows a Fast Track designation to Johnson & Johnson's nipocalimab for treating moderate-to-severe Sjogren's disease ...

Century Therapeutics has joined the onslaught of cell therapy biotechs taking hits, discontinuing a phase 1 cancer study to ...

Rheumatologists and cardiologists have long co-managed patients out of necessity and without much formal collaboration or ...

Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and ...

Abdelghani M, et al . Experimental myositis: an optimised version of C-protein-induced myositis. RMD Open 2025;11:e004558. doi: 10.1136/rmdopen-2024–0 04 558 In this article, the abstract has been ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...